NCT05553236Recruiting
Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
Source: ClinicalTrials.gov · Last updated 26 Jan 2026
Brief summary (registry, in English)
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 2500 (estimated)
- First submitted
- 12 Sept 2022
- Start date
- 1 Aug 2024
- Primary completion date
- Jan 2027
- Lead sponsor
- University of California, San Francisco
- Diseases
- Tuberculosis, HIV
- NCT number
- NCT05553236
What you commit to
- Study type: Interventional
- Planned participants: 2500
- From 1 Aug 2024 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient expects to relocate/move residence outside of the study region
- Patient does not agree to participate in the study
- In addition, participants later found to have isolates with rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be considered late exclusions.
Who the study is looking for
- Active RR-TB diagnosed at a study facility during the study period
- Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| South African National Health Laboratory Service Coordinator of this site? Confirm its status | Cape Town | South Africa | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.